The aim of this observational prospective study was to evaluate the switch from phytotherapy to tamsulosin 0.4 mg once daily (o.d.) on efficacy, sexual function and tolerability in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) who have a poor response to at least 4 weeks of phytotherapy. The switch to tamsulosin 0.4 mg o.d. improves LUTS and related quality of life. Sexual function is also slightly improved. Tamsulosin is as well tolerated as phytotherapy and abnormal ejaculation appears to be no problem. Tamsulosin is perceived by both patients and urologists to be superior to preceding phytotherapy.
Introduction
Many older men present to their general practitioner (GP) with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Nocturia, urinary incontinence and/or urgency are some of the symptoms that bother the patient most since they may cause embarrassment or interfere with daily life activities. LUTS/BPH may also lead to more serious conditions such as acute urinary retention (AUR) in the longterm progress. Two community-based studies showed that LUTS/BPH, usually defined as an International Prostate Symptom Score (I-PSS) X8, occur in approximately 25% of men aged 40 y and over and that the prevalence rises with increasing age. 1, 2 As the population in many countries is ageing, it is expected that the number of men presenting with urinary symptoms in clinical practice will also increase extensively in the coming 10-20 y. This calls for an effective therapy that will improve troublesome symptoms and prevent progression with negligible side effects. a 1 -adrenoceptor (AR) antagonists have become the mainstay of medical therapy for LUTS/BPH. 3 The a 1A / a 1D -AR antagonist tamsulosin 0.4 mg once daily (o.d.) has been shown in randomised controlled trials to provide a rapid and effective relief of urinary symptoms with a favourable tolerability. 4 It is currently the most prescribed a 1 -AR antagonist for LUTS/BPH worldwide. 5 In some countries, such as Germany and France, phytotherapy is also widely used. 3, 6 This may be related to their perceived good tolerability. However, scientific evidence regarding the efficacy (and tolerability) of phytotherapy from placebo-controlled, randomised trials with long-term follow-up is largely lacking. Therefore, in contrast to a 1 -AR antagonists, phytotherapy is not recommended for the treatment of LUTS/BPH by the 5th International Consultation on BPH 7 and the American Urological Association (AUA) guideline on the management of BPH. 8 The Guidelines of the German Urologic Association indicate that patients with LUTS/BPH and a total I-PSS X8 should receive effective therapy. Therefore, this German postmarketing surveillance (PMS) study evaluated in LUTS/BPH patients with poor response to phytotherapy the switch to tamsulosin both from an efficacy and tolerability point of view.
Materials and methods

Study design
This was an observational, nonrandomised, non-controlled, non-blinded prospective study. It was designed as a PMS study to collect post-marketing information on tamsulosin. Patients were treated with tamsulosin 0.4 mg o.d. for at least 2 months after they had been treated with at least 4 weeks of phytotherapy but without adequate response.
Study population
Patients were included in the study if they had received at least 4 weeks of phytotherapy for LUTS/BPH but still had a total I-PSS X8 points and had an indication for tamsulosin 0.4 mg o.d. treatment for a period of at least 2 months.
Patients were excluded if they fulfilled any of the general or specific contraindications listed in the tamsulosin summary of product characteristics (SPC), particularly if there was a known hypersensitivity against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency. In addition, patients receiving tamsulosin 0.4 mg o.d. within the 4 weeks prior to the start of the study were excluded.
Assessment of efficacy
Primary efficacy variables were total I-PSS 9 and the I-PSS quality of life (QoL) score. 7 For the I-PSS, the patient had to rate the frequency of seven urinary symptoms (four related to voiding and three related to storage symptoms) on a scale from 0 to 5 with a total score range from 0 to 35. The QoL score (also referred to as the bother score) asks patients to indicate how they would feel if they were to spend the rest of their life with the urinary condition as it was at the time of completing the questionnaire (scale from 0 to 6).
Secondary efficacy variables were maximum flow rate (Q max ) and postvoid residual (PVR). In addition, the patient had to rate his satisfaction with the preceding phytotherapy and with tamsulosin as satisfied, partly satisfied or not satisfied. He also had to compare tamsulosin treatment with previous phytotherapy treatment by indicating which treatment was superior or whether there was no large difference. The same question was asked to the physician. In addition, the physician had to rate the global efficacy of preceding phytotherapy and tamsulosin on a scale using the categories very good, good, moderate to poor.
A sexual satisfaction inventory was performed to evaluate the effect of the treatment switch on sexual function. The patient was asked to rate his sexual satisfaction as satisfied, partly satisfied, not satisfied or sexuality does not play an important role. Furthermore, the physician reported sexual problems in the patient's life such as hygiene problems due to micturition disorders (eg smelling, dirty underwear), lack of libido, erectile dysfunctions, orgasm disorders and lack of satisfaction during sexual activities.
All efficacy parameters were assessed after phytotherapy treatment and after X2 months of tamsulosin treatment.
Assessments of tolerability
Treatment tolerability was assessed by means of adverse drug reactions (ADRs). In addition, the physician was asked to rate the global tolerability of preceding phytotherapy and tamsulosin treatment on a scale with very good, good, satisfied or poor.
Statistical methods and sample size
All patients with at least the date of the baseline visit were included in the safety set, which was used to analyse data on tolerability. Efficacy parameters were analysed using the full analysis set, which comprised all patients of the safety set who fulfilled the inclusion criteria and for whom a total I-PSS was available at baseline and after X2 months of tamsulosin treatment. As this was an observational study descriptive statistical methods and frequency tables were used to describe the data using the software package SAS. In case of missing data no transformations were performed on the data. Queries were also not generated.
A total of 5000 case report forms (CRFs) were distributed to participating physicians in order to obtain a sample size of at least 3000 treated patients.
Results
Patients
A total of 4150 patients were enrolled in the study, of these 4123 patients constituted the safety set and 3322 patients the full analysis set.
A total of 112/4123 patients (2.7%) discontinued prematurely. The most frequent reasons for discontinuation were deterioration of LUTS/BPH (32/4123 patients or 0.78%), loss to follow-up (31/4123 patients or 0.75%) and other events not related to tamsulosin (28/4123 patients or 0.68%). In 15/4123 patients (0.36%) treatment was discontinued due to adverse events.
Baseline characteristics
Baseline characteristics of the safety set are shown in Table 1 . The mean age was 66 y, the mean total I-PSS 16.2 points and approximately 40% of patients had cardiovascular comorbidity/medication. Table 2 shows the change in efficacy parameters after X2 months of tamsulosin treatment compared to preceding phytotherapy. Switching from phytotherapy to tamsulosin Switch from phytotherapy to tamsulosin in LUTS/BPH AJ Gross et al improved total I-PSS by 41% (6.9/16.7) and I-PSS QoL by 46% (1.6/3.5). The percentage of patients with a total I-PSS o8 increased from 0 to 31.2% (1035/3322). In addition Q max improved by 38% (4.4/11.7) and PVR by 58% (35.9/61.4).
Efficacy
The switch from phytotherapy to tamsulosin increased the patients' satisfaction with therapy. A total of 2868/ 3293 (87.1%) of patients were satisfied with tamsulosin vs 138/3291 (4.2%) for preceding phytotherapy (Figure 1 ). In addition, in 3107/3308 (93.9%) cases urologists rated the efficacy of tamsulosin as very good to good vs 347/ 3318 (10.5%) for preceding phytotherapy (Figure 1) .
The percentage of patients indicating to be satisfied with their sexual life increased from 31.6% (872/2763) to 43.3% (1198/2766). The percentage of patients with no sexual problems according to the urologist also increased from 37.0% (1228/3322) to 45.1% (1499/3322; Figure 2 ). This was most pronounced with respect to erectile dysfunction and decreased libido.
A total of 94.1% (3069/3261) of patients perceived tamsulosin to be superior to phytotherapy. This is in line with the perception of urologists who found tamsulosin to be superior in 94.4% (3042/3224) of cases.
Tolerability
ADRs were reported for 0.5% of the patients (20/4123: Table 3 ). Dizziness and circulatory instability were the most frequent ADRs. 0.36% of patients (15/4123) discontinued treatment because of ADRs. The most frequent ADRs leading to discontinuation were dizziness (5/4123; 0.12%) and circulatory instability (3/4123; 0.07%). In all, 0.05% of patients (2/4123) discontinued treatment due to abnormal (retrograde) ejaculation.
94.0% (3105/3302) and 97.4% (3221/3307) of physicians rated the tolerability of phytotherapy and tamsulosin, respectively, as good to very good (Figure 3 ). Switch from phytotherapy to tamsulosin in LUTS/BPH AJ Gross et al
Discussion Efficacy
In LUTS/BPH patients with a poor response to at least 4 weeks of phytotherapy, switching to tamsulosin 0.4 mg o.d. improves LUTS/BPH and related QoL. LUTS/BPH variables are improved by at least 40% after X2 months tamsulosin treatment relative to preceding phytotherapy. In addition, switching from phytotherapy to tamsulosin increases patients' and urologists' satisfaction with (the efficacy of) treatment: the increase in the percentage of patients being satisfied with increased response is approximately 80%. In one large German observational survey in which almost 10 000 patients with LUTS/BPH received tamsulosin 0.4 mg o.d. for 4 weeks, patients pretreated with other medical therapy such as phytotherapy were asked to rate the global efficacy (and tolerability) of tamsulosin in comparison with their previous treatment (ie worse, similar, better). 10 It appeared that the global efficacy of tamsulosin was perceived as better than that of previous treatment in about 86-88% of patients pretreated with phytotherapy. As the efficacy of tamsulosin and other a 1 -AR antagonists is comparable, the response in the a 1 -AR antagonist group of pretreated patients (63%) can be taken as a comparison/baseline which leaves around 25% of patients with better efficacy when switching from phytotherapy to tamsulosin. Although observational studies are not designed to compare the efficacy of tamsulosin with that of phytotherapy, this seems to indicate that the efficacy of tamsulosin is (perceived as) better than that of preceding phytotherapy when patients are switched to tamsulosin. However, it is not known which type of phytotherapy (eg Serenoa repens, Pygeum afriacanum, b-sitosterol) was taken by the patients so no statements regarding individual agents can be made. The results from randomised, direct-comparative trials are inconsistent. One double blind, randomised, directcomparative 1 y study that compared tamsulosin with the plant extract S. repens in 811 men with LUTS/BPH showed comparable efficacy of both treatments. 11 On the other hand, two short-term, small comparative studies against a 1 -AR antagonists have shown better symptom relief with the a 1 -AR antagonists than phytotherapy. 12, 13 The difference is probably due to the short treatment duration in the two smaller studies as in the larger, 1 y study, tamsulosin also appeared to provide a faster/ better response in the short term. 11 The problems with this latter study were, however, that no placebo arm was included, the patient population was different from that usually enrolled into placebo-controlled studies with tamsulosin [14] [15] [16] [17] (prostate volume 48 ml 11 vs 31 g 18 ) and that although the percentage of patients that discontinued due to insufficient response was larger in the phytotherapy (4.3%) than tamsulosin (2.3%) group, the per protocol instead of intent-to-treat/full analysis set results were reported.
Switching from phytotherapy to tamsulosin 0.4 mg o.d. also slightly improved sexual life in the opinion of the patients and increased the percentage of patients with no sexual problems according to the physicians. In placebocontrolled and direct-comparative studies tamsulosin and other a 1 -AR antagonists have also been shown to slightly improve overall sexual function. 19 This may reflect the improvement in QoL associated with the relief of urinary symptoms. It is likely that as LUTS become less bothersome, patients become less 'disabled' by their urinary symptoms, and are better able to enjoy other aspects of life without feeling inhibited or limited by their LUTS. In addition, it may also be a direct pharmacological effect of a 1 -AR antagonists on a 1 -ARs in the penile arteries and/or the corpus cavernosum resulting in relaxation of smooth muscle and subsequent increase in blood flow into the lacunar spaces of the corpora cavernosa. 19 
Tolerability
The switch from phytotherapy to tamsulosin is very well tolerated as over 90% of urologists rated the tolerability of both treatments to be good to very good. As is the case for efficacy, because it is not known which type of phytotherapy was taken by the patients, no statements regarding individual agents can be made. Almost onethird of the patients included in this observational study was older than 71 y and about 40% had cardiovascular comorbidity and/or comedication. Although no subset analysis was performed it appears that the good tolerability of tamsulosin is also maintained in these patients. In two large German observational studies the patients previously receiving phytotherapy also rated the global tolerability of tamsulosin 0.4 mg o.d. to be similar to that of their previous treatment. 10 The randomised, Figure 3 Percentage of urologists rating the tolerability of treatment to be good/very good.
Switch from phytotherapy to tamsulosin in LUTS/BPH AJ Gross et al double-blind, direct-comparative study between tamsulosin 0.4 mg o.d. and S. repens also confirms the good tolerability of tamsulosin vs phytotherapy. 11 With the exception of abnormal ejaculation (4.2 vs 0.4% for tamsulosin 0.4 mg o.d. vs S. repens, respectively), the side effect profile was comparable for both treatments. This included the incidence of dizziness, fatigue/asthenia, and postural hypotension and the percent of patients discontinuing due to adverse events (8.2 vs 7.7% for tamsulosin 0.4 mg o.d. vs S. repens, respectively).
In this observational study few patients (0.05%) discontinued due to retrograde ejaculation. Also in randomised controlled trials with tamsulosin few patients stopped treatment because of abnormal ejaculation (o1%). 19, 20 Therefore, abnormal ejaculation does not appear to be perceived as troublesome by patients experiencing this adverse event on tamsulosin, also in real-life clinical practice.
Conclusions
In LUTS/BPH patients with poor response to at least 4 weeks of phytotherapy switching to tamsulosin markedly improves LUTS/BPH and related QoL. The switch from phytotherapy to tamsulosin also seems to slightly improve sexual function. Tamsulosin seems to be as well tolerated as phytotherapy. Abnormal ejaculation appears to be no problem in patients treated with tamsulosin in clinical practice. Tamsulosin 0.4 mg o.d. is perceived by the majority of patients and urologists to be very effective and superior to phytotherapy.
